Press Release
BIOASTER – Lyon, France, ZYNNON AG – Schindellegi, Switzerland, September 26, 2024
BIOASTER and ZYNNON are excited to announce a strategic collaboration focused on the innovative use of volatile organic compounds (VOCs) for the detection and identification of infections in clinical and industrial microbiology labs. This groundbreaking partnership aims to enhance diagnostic accuracy and efficiency for a wide range of infections caused by bacterial and fungal pathogens.
The technology stands out for its ability to directly measure VOCs released during the growth of these pathogens. This advancement reduces sample handling complexity and minimizes contamination risks, streamlining the diagnostic process. Recent laboratory tests performed at BIOASTER have demonstrated the effectiveness of the solution with key bacterial strains, including Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. By integrating pathogen detection and identification into a single unit, the system simplifies workflows and significantly enhances both accuracy and speed.
“This collaboration with ZYNNON marks an exciting milestone in our mission to improve diagnostic methodologies” said Xavier Morge, CEO of BIOASTER. “Our combined expertise in diagnostics and microbiology will enable us to develop a tool that not only simplifies laboratory processes but also delivers rapid and reliable results for infection detection.”
Khaled Abousaleh, CEO of ZYNNON states: “We are excited to partner with BIOASTER, leveraging their strong expertise in microbiology and diagnostics, to advance our innovative technology and expand its impact in both clinical and industrial markets. Together, we aim to enhance diagnostics and healthcare on a large scale, improve patient outcomes, and contribute to the global fight against antimicrobial resistance (AMR).”
Together, BIOASTER and ZYNNON are committed to advancing infection detection technologies that improve operational efficiency in microbiology labs. This partnership promises to address critical needs in the field of infectious diseases and contribute to better public health outcomes through innovative solutions. We look forward to sharing more updates as we progress in our collaborative efforts.
About ZYNNON
Zynnon (www.zynnon.com) is a startup transforming infectious pathogen diagnostics, minimizing operations within the laboratory and speeding up the transmission of vital pathogen information to the treating physician in order to optimize treatments and improve patient outcomes. This gaseous biomarker-based solution for the detection of Volatile Organic Compounds (“VOCs”) is used to rapidly and precisely identify bacterial and fungal pathogens to the genus and species level. The VOC-detection and differentiation technology serves as a rapid and efficient alternative or add-on to traditional pathogen identification laboratory methods, substantially shortening the timeline from sample collection to actionable lab results. By streamlining complex procedures into a simple, small, compact, and easy-to-operate sensor-based VOC detector, along with a validated VOC database, the need for specialized laboratory skills for pathogen detection and classification (such as PCR and/or immunoassay-based techniques) is eliminated.
Disclaimer : Not CE-marked, not FDA approved. Product not available on the market, not for sale.
About BIOASTER
Created in 2012, following the French initiative of Technology Research Institutes, BIOASTER is a not-for-profit foundation developing a unique technological and innovative model to support the latest challenges in microbiology. In particular, BIOASTER uses and develops high value technological innovations that accelerate the development of medical solutions for populations and for personalized medicine. The aim of BIOASTER is to bring together academic, industry and their capacities and specific knowledge to develop and execute high impact collaborative projects requiring industry compatible innovative technologies.
Key figures:
• 4 fields of expertise: antimicrobials, diagnostics, microbiota, vaccines
• BSL2 & BSL3 laboratories in Lyon and Paris
• 100+ employees, including 80% of scientific experts, 17 nationalities
• 400+ research contracts, involving 107 private partners, 54 public partners. 13 Grants & European projects.
For media inquiries and additional information, please contact:
For ZYNNON:
Alex Marc
CFO & Investor Relations Manager
Zynnon AG
Phone: +41 79 455 40 30
Email: alex.marc@zynnon.com
For BIOASTER:
Press contact: olivier.charzat@bioaster.org